Hepatitis B vaccine (
HepB), which has been available since 1982, provides lifelong protection against hepatitis B virus (HBV)
infection and the associated 20%-30% increased lifetime risk for developing
cirrhosis or
hepatocellular carcinoma among >95% of
vaccine recipients (1). Before
HepB introduction into national childhood immunization schedules, the estimated
hepatitis B surface antigen (
HBsAg) prevalence in the World Health Organization (WHO) Western Pacific Region (WPR)* was >8% in 1990 (2). In 2005, the WPR was the first WHO region to establish a
hepatitis B control goal, with an initial target of reducing
HBsAg prevalence to <2% among children aged 5 years by 2012. In 2013, the WPR set more stringent control targets to achieve by 2017, including reducing
HBsAg prevalence to <1% in children aged 5 years and increasing national coverage with both timely
HepB birth dose (
HepB-BD) (defined as administration within 24 hours of birth) and the third
HepB dose (HepB3) to ≥95% (3). All WPR countries/areas endorsed the Regional Action Plan for Viral
Hepatitis in the Western Pacific Region 2016-2020 in 2015 (4) and the Regional Framework for the Triple Elimination of Mother-to-Child Transmission of human immunodeficiency virus (HIV),
Hepatitis B and
Syphilis in Asia and the Pacific 2018-2030 (triple elimination framework) in 2017 (5). These regional targets and strategies are aligned with program targets established by the WHO Global Health Sector Strategy on Viral
Hepatitis 2016-2021 that aim to reduce
HBsAg prevalence among children aged 5 years to ≤1% by 2020 and to ≤0.1% by 2030 (6). This report describes progress made to achieve
hepatitis B control in the WPR and the steps taken to eliminate mother-to-child transmission (MTCT) of HBV during 2005-2017. During this period, regional timely
HepB-BD and HepB3 coverage increased from 63% to 85% and from 76% to 93%, respectively. As of December 2017, 15 (42%) countries/areas achieved ≥95% timely
HepB-BD coverage; 18 (50%) reached ≥95% HepB3 coverage; and 19 (53%) countries/areas as well as the region as a whole were verified to have achieved the regional and global target of <1%
HBsAg prevalence among children aged 5 years. Continued implementation of proven vaccination strategies will be needed to make further progress toward WPR
hepatitis B control targets. In addition to high
HepB-BD and HepB3 coverage, enhanced implementation of complementary
hepatitis B prevention services through the triple elimination framework, including routine
HBsAg testing of pregnant women, timely administration of
hepatitis B immunoglobulin to exposed newborns, and
antiviral treatment of mothers with high viral loads, will be needed to achieve the global
hepatitis B elimination target by 2030.